Difference between revisions of "Altretamine (Hexalen)"
Jump to navigation
Jump to search
m |
m (categories) |
||
| Line 17: | Line 17: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Alkylating agents]] | ||
| + | [[Category:Ovarian cancer medications]] | ||
Revision as of 22:08, 7 October 2012
Also known as Hexamethylmelamine or HMM.
General information
Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Altretamine (Hexalen) patient drug information (Chemocare)[3]
- Altretamine (Hexalen) patient drug information (UpToDate)[4]